Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798963
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798963
Multiple Sclerosis Therapeutics
PUBLISHED:
PAGES: 268 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Multiple Sclerosis Therapeutics Market to Reach US$35.8 Billion by 2030
The global market for Multiple Sclerosis Therapeutics estimated at US$30.1 Billion in the year 2024, is expected to reach US$35.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Large-molecule Drugs, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$23.2 Billion by the end of the analysis period. Growth in the Small-molecule Drugs segment is estimated at 1.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$8.2 Billion While China is Forecast to Grow at 5.7% CAGR
The Multiple Sclerosis Therapeutics market in the U.S. is estimated at US$8.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.0 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.
Global Multiple Sclerosis Therapeutics Market - Key Trends & Drivers Summarized
Why Is the Treatment Landscape for Multiple Sclerosis Undergoing Rapid Evolution?
Multiple sclerosis (MS), a chronic, inflammatory, demyelinating disorder of the central nervous system, has historically lacked curative options, but the therapeutic landscape is rapidly evolving. The emergence of targeted immunomodulatory and immunosuppressive agents has transformed MS from a debilitating disease with poor prognosis into a manageable condition for many patients. The development pipeline is expanding beyond traditional disease-modifying therapies (DMTs) into monoclonal antibodies, sphingosine-1-phosphate (S1P) receptor modulators, B-cell depleting agents, and gene-based interventions.
The classification of MS into subtypes-relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS)-has led to more nuanced treatment regimens that consider disease stage, activity level, and patient-specific immune responses. Monoclonal antibodies such as ocrelizumab and ofatumumab have shown success in slowing disease progression, especially in PPMS where earlier treatments were largely ineffective. Oral agents like fingolimod and dimethyl fumarate offer convenience, leading to improved adherence in long-term disease management.
What Scientific and Technological Breakthroughs Are Redefining MS Therapy?
Scientific advancements in the understanding of MS pathogenesis, particularly the role of B-cells, cytokine signaling, and gut-brain axis interactions, are unlocking new therapeutic strategies. The focus has shifted from non-specific immunosuppression to selective immune modulation, enabling better efficacy with fewer adverse events. Anti-CD20 therapies are gaining ground due to their ability to reduce relapse rates and lesion formation without compromising long-term immune surveillance.
Next-generation therapies are exploring remyelination and neuroprotection. Experimental agents such as clemastine fumarate and opicinumab are being investigated for their potential to promote oligodendrocyte regeneration and axonal repair. mRNA-based therapies and gene-editing technologies are also in preclinical stages, targeting the correction of immune dysfunction at the molecular level.
Biomarker development is aiding in personalized therapy selection and early diagnosis. MRI-based lesion tracking, serum neurofilament light chain (NfL) levels, and HLA genotyping are becoming tools for therapeutic monitoring and stratified treatment planning. Digital health platforms are emerging to support remote patient monitoring, relapse detection, and medication adherence through mobile apps and wearable devices-improving clinical outcomes and enabling real-world evidence generation.
Which Patient Demographics, Drug Classes, and Regional Dynamics Are Driving Demand?
The prevalence of MS is highest in North America and Europe, with increasing diagnosis rates in Asia-Pacific and Latin America due to improved awareness and diagnostic capabilities. RRMS remains the most commonly diagnosed form, but the share of PPMS and SPMS is growing as diagnostic imaging and biomarker usage increase. Younger adults (aged 20-40), particularly women, constitute the majority of new diagnoses, making long-term therapy adherence and safety profiles key market considerations.
Oral DMTs are the most widely used therapies in terms of volume, but monoclonal antibodies account for the largest market share by revenue due to higher pricing and hospital-based administration models. B-cell therapies, S1P receptor modulators, and integrin inhibitors are the leading classes shaping current treatment regimens. Meanwhile, adjunct therapies including corticosteroids, muscle relaxants, and antidepressants continue to support symptom relief, especially in progressive disease cases.
The U.S. leads global MS therapeutic sales due to high healthcare expenditure, favorable reimbursement, and faster regulatory approvals. Europe, particularly Germany, France, and the U.K., follows closely with strong uptake of biologics. Emerging markets in Asia-Pacific are becoming attractive for generic DMTs and biosimilars as health systems expand neurological care infrastructure. Patient advocacy organizations are also influencing treatment access, pricing policies, and clinical trial participation globally.
What Is Fueling Growth in the Global Multiple Sclerosis Therapeutics Market?
The growth in the global multiple sclerosis therapeutics market is driven by several factors, including increasing disease prevalence, improved diagnostic practices, and a robust innovation pipeline targeting multiple pathogenic pathways. The diversification of therapeutic options, from broad immunosuppressants to highly specific monoclonal antibodies and oral agents, is allowing physicians to tailor treatments based on individual patient profiles, disease subtypes, and biomarker expression.
Advances in molecular biology, immunology, and neurodegeneration research are expanding the horizon for next-generation therapies focused on neurorepair and long-term remission. Coupled with improvements in clinical trial design, regulatory support for orphan and fast-track designations, and a growing investment landscape, the pace of drug development in MS is accelerating. The transition toward value-based care and real-world evidence is encouraging the development of digital tools and companion diagnostics that enhance treatment efficacy and patient engagement.
Growing awareness, improved access to neurologists, and rising healthcare expenditure are driving market expansion in both developed and emerging economies. Biosimilars, extended-release formulations, and alternative administration routes are reducing barriers to entry in cost-sensitive markets. As personalized medicine becomes central to chronic disease management, the multiple sclerosis therapeutics market is poised for sustained growth, with new entrants and innovative mechanisms continuing to reshape the treatment paradigm.
SCOPE OF STUDY:
The report analyzes the Multiple Sclerosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Type (Large-molecule Drugs, Small-molecule Drugs); Administration Route (Oral Administration Route, Injectable Administration Route, Other Administration Routes)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
- AbbVie Inc.
- Actelion Pharmaceuticals Ltd (Johnson & Johnson)
- Acorda Therapeutics Inc.
- Adamas Pharmaceuticals Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- EMD Serono (Merck KGaA)
- Evotec SE
- Glenmark Pharmaceuticals Ltd.
- GlaxoSmithKline plc (GSK)
- Hoffmann-La Roche Ltd. (Genentech)
- Johnson & Johnson
- Mapi Pharma Ltd.
- Mylan N.V. (now part of Viatris)
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Product Code: MCP39080
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Multiple Sclerosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Advances in Immunomodulatory Drug Classes Spur Growth in Multiple Sclerosis Therapeutics
- Expansion of Monoclonal Antibody Pipelines Strengthens Market for MS Disease-Modifying Therapies
- Progress in Remyelination Research Expands Addressable Market for Novel MS Treatments
- Biomarker-Based MS Diagnostics Propel Precision Therapeutic Strategies
- Growing Global Awareness Campaigns Drive Early Diagnosis and Treatment Uptake in MS Care
- Adoption of Oral Sphingosine-1-Phosphate Modulators Strengthens Business Case for First-Line Therapy Shifts
- Rising Use of MRI in Disease Monitoring Spurs Optimization of MS Treatment Protocols
- Regulatory Fast-Track Approvals Accelerate Market Entry of Innovative MS Drug Candidates
- Pediatric MS Diagnosis Trends Throw the Spotlight on Age-Specific Therapeutic Formulations
- Shift Toward Once-Daily Dosing Regimens Drives Patient Adherence in MS Treatment
- Increasing Use of Digital Adherence Platforms Supports Long-Term MS Drug Compliance
- Geographic Expansion of MS Patient Support Programs Spurs Therapeutic Uptake in Emerging Markets
- Advances in CNS Drug Delivery Systems Improve Bioavailability of MS Therapies
- Collaborations Between Academia and Biotech Firms Accelerate Neurodegeneration-Focused MS Research
- Patient Demand for Improved Tolerability Drives Transition Toward Second-Generation MS Therapies
- Expanded Label Indications for Existing Biologics Create New Revenue Streams in MS Market
- Real-World Evidence Collection Strengthens Payer Confidence in High-Cost MS Therapies
- Targeted B-Cell Depletion Therapies Propel Competitive Differentiation in MS Biopharma Space
- Chronic Disease Management Models in Neurology Propel Demand for Long-Acting MS Therapeutics
- Post-COVID Telemedicine Integration Expands Access to MS Specialist Consultations and Drug Refills
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Multiple Sclerosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Large-molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Large-molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Large-molecule Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Small-molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Small-molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Small-molecule Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Injectable Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: USA 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: USA 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: Canada 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: Canada 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- JAPAN
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Japan 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Japan 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- CHINA
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: China 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: China Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: China 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- EUROPE
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Europe 16-Year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- FRANCE
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: France 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: France Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: France 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- GERMANY
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: Germany 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: Germany 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: Italy 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Italy 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: UK 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: UK 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 77: Spain Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Spain Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Spain 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 80: Spain Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Spain Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: Spain 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 83: Russia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Russia Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Russia 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 86: Russia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Russia Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Russia 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Rest of Europe 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of Europe Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Rest of Europe 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- AUSTRALIA
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 104: Australia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Australia Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: Australia 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 107: Australia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Australia Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: Australia 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- INDIA
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 110: India Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: India Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 112: India 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 113: India Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: India Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 115: India 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 116: South Korea Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: South Korea Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 118: South Korea 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 119: South Korea Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: South Korea Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 121: South Korea 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Asia-Pacific Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Rest of Asia-Pacific Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 128: Latin America Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 129: Latin America Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 130: Latin America 16-Year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 133: Latin America 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 137: Argentina Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Argentina Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 139: Argentina 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 140: Argentina Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Argentina Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 142: Argentina 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 143: Brazil Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Brazil Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 145: Brazil 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 146: Brazil Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Brazil Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 148: Brazil 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 149: Mexico Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Mexico Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 151: Mexico 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 152: Mexico Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Mexico Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 154: Mexico 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Rest of Latin America Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 157: Rest of Latin America 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Rest of Latin America Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 160: Rest of Latin America 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 161: Middle East Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 162: Middle East Historic Review for Multiple Sclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 163: Middle East 16-Year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 164: Middle East Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Middle East Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 166: Middle East 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 169: Middle East 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- IRAN
- TABLE 170: Iran Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Iran Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 172: Iran 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 173: Iran Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Iran Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 175: Iran 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 176: Israel Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Israel Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 178: Israel 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 179: Israel Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Israel Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 181: Israel 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Saudi Arabia Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 184: Saudi Arabia 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: Saudi Arabia Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 187: Saudi Arabia 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 188: UAE Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: UAE Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 190: UAE 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 191: UAE Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: UAE Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 193: UAE 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Middle East Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 196: Rest of Middle East 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Middle East Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 199: Rest of Middle East 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
- AFRICA
- Multiple Sclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 200: Africa Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Africa Historic Review for Multiple Sclerosis Therapeutics by Drug Type - Large-molecule Drugs and Small-molecule Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 202: Africa 16-Year Perspective for Multiple Sclerosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Large-molecule Drugs and Small-molecule Drugs for the Years 2014, 2025 & 2030
- TABLE 203: Africa Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Africa Historic Review for Multiple Sclerosis Therapeutics by Administration Route - Oral Administration Route, Injectable Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 205: Africa 16-Year Perspective for Multiple Sclerosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Other Administration Routes for the Years 2014, 2025 & 2030
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.